Eli Lilly and Co (LLY)

76.32
0.49 0.64
NYSE : Health Care
Prev Close 76.81
Open 76.24
Day Low/High 76.16 / 76.88
52 Wk Low/High 64.18 / 83.78
Volume 5.05M
Avg Volume 6.40M
Exchange NYSE
Shares Outstanding 1.10B
Market Cap 84.83B
EPS 2.30
P/E Ratio 33.41
Div & Yield 2.08 (2.70%)

Latest News

Must-Know Tricks On Trading Goldman Sachs, Ford and Other Very Active Stocks

Must-Know Tricks On Trading Goldman Sachs, Ford and Other Very Active Stocks

Here's how to trade some of the most active stocks on the market Wednesday.

Stocks Struggle for Direction as Economic Improvements May Push Fed Moves

Stocks Struggle for Direction as Economic Improvements May Push Fed Moves

Stocks struggle for direction on Wednesday as a strengthening U.S. economy reinforces the chances of several rate hikes this year.

Stock Futures Inch Higher as Citigroup, Goldman Sachs Get Trading Boost

Stock Futures Inch Higher as Citigroup, Goldman Sachs Get Trading Boost

Stock futures inch higher as Citigroup and Goldman Sachs join the series of banks that enjoyed a trading boost in the fourth quarter.

Jazz Pharma, CoLucid Spike Premarket, Plus Other Biotech Movers

Jazz Pharma, CoLucid Spike Premarket, Plus Other Biotech Movers

CoLucid Pharmaceuticals saw shares boost 32% ahead of the market open Wednesday.

Eli Lilly Acquires CoLucid Pharma, Adds Migraine Drug to Pipeline

Eli Lilly Acquires CoLucid Pharma, Adds Migraine Drug to Pipeline

CoLucid will be acquired for $46.50 per share, a 33% premium to the stock's closing price Tuesday.

Patent Victory Secures Lilly Hold on Cancer Drug Until 2022

Patent Victory Secures Lilly Hold on Cancer Drug Until 2022

An appeals court in Indiana upheld Eli Lilly's patent regarding Alimta, a major cancer drug for Lilly, keeping Teva and other generic drug specialists at bay.

4 Biotech Names That Could Be M&A Targets

4 Biotech Names That Could Be M&A Targets

Animal health and oncology deal activity is heating up in 2017.

3 Takeover Candidates in the Drug Space

3 Takeover Candidates in the Drug Space

Potential acquirers include Gilead Sciences, Johnson & Johnson, Pfizer, Merck and Novartis.

3 Takeover Candidates in the Drug Space

3 Takeover Candidates in the Drug Space

Potential acquirers include Gilead Sciences, Johnson & Johnson, Pfizer, Merck and Novartis.

Drug Giant Eli Lilly Wants to Save Money So it Brought in These New Bigwigs

Drug Giant Eli Lilly Wants to Save Money So it Brought in These New Bigwigs

One of the announcements include the hiring of former Novartis executive Christi Shaw to lead the biomedicines business starting April 3.

Senate Dems, D.C. Watchdog Call for Investigation Into Trump HHS Pick Tom Price's Stock Portfolio

Senate Dems, D.C. Watchdog Call for Investigation Into Trump HHS Pick Tom Price's Stock Portfolio

Congressional Republicans who scrapped plans to overhaul the Office of Congressional Ethics might be regretting their decision. Senate Dems are asking for an investigation into HHS pick Tom Price.

Elanco Animal Health Completes Acquisition Of Boehringer Ingelheim Vetmedica's U.S. Feline, Canine And Rabies Vaccines Portfolio

Elanco Animal Health Completes Acquisition Of Boehringer Ingelheim Vetmedica's U.S. Feline, Canine And Rabies Vaccines Portfolio

Eight new product lines and a fully integrated manufacturing and R&D site transfer to Elanco

Analysts Mixed on Health Care Stocks in the New Year

Analysts Mixed on Health Care Stocks in the New Year

While there is deep uncertainty about how politics will affect the health care sector in the new year, analysts seem excited about some opportunities in pharmaceuticals.

Drugs Were a Downer in 2016 and Could Be Again in 2017: Exane BNP

Drugs Were a Downer in 2016 and Could Be Again in 2017: Exane BNP

The key trends for 2016 were falling insulin prices, falling returns on R&D and lower approval rates, according to analysts at the French bank.

Allergan, Apple, Oakland Capital: Doug Kass' Views

Allergan, Apple, Oakland Capital: Doug Kass' Views

Doug Kass shares his thoughts on China and life insurers.

White House Kills Plan for Drug Price Cap

White House Kills Plan for Drug Price Cap

Pelosi, Schumer and nearly everyone else had asked Obama to deep-six the deal.

Boehringer Ingelheim And Lilly Welcome New Recommendation For Jardiance® (empagliflozin) Tablets In Updated American Diabetes Association's 2017 Standards

Boehringer Ingelheim And Lilly Welcome New Recommendation For Jardiance® (empagliflozin) Tablets In Updated American Diabetes Association's 2017 Standards

Guidelines include new recommendation to consider the use of JARDIANCE in people with type 2 diabetes and established cardiovascular disease to reduce the risk of cardiovascular death

Analysts' Actions -- GE, Nordstrom, Coca-Cola, Eli Lilly and More

Analysts' Actions -- GE, Nordstrom, Coca-Cola, Eli Lilly and More

Here are Friday's top research calls, including upgrades for Eli Lilly, Regeneron and GE, and downgrades for Nordstrom, Coca-Cola, Apache and Duke Energy.

Stocks Stop Short of Records in Rebound Rally After Fed's Rate Hike

Stocks Stop Short of Records in Rebound Rally After Fed's Rate Hike

Wall Street moved higher on Thursday, though it fell shy of new records, in a rebound session following the Federal Reserve-triggered selloff a day earlier.

Technical Analysis Shows Trio of Healthcare Stocks May Not Be Buys Yet

Technical Analysis Shows Trio of Healthcare Stocks May Not Be Buys Yet

The charts for Cerner, Eli Lilly and McKesson do not flash buy signals.

Stocks Higher as Banks Lead Wall Street Rebound

Stocks Higher as Banks Lead Wall Street Rebound

Stocks rebound on Thursday after a knee-jerk selloff late Wednesday tied to the Federal Reserve's rate hike outlook.

Inside Eli Lilly's Surging Stock Price

Inside Eli Lilly's Surging Stock Price

For the first time in three years, Eli Lilly's guidance for next year has topped Wall Street's consensus estimates.

Eli Lilly Surges After 2017 Guidance Beats Street Forecast

Eli Lilly Surges After 2017 Guidance Beats Street Forecast

Eli Lilly shares are up after the drugmaker offered 2017 earnings guidance above Wall Street's forecast.

Dow Back on Track for 20,000 as Wall Street Rebounds From Fed Selloff

Dow Back on Track for 20,000 as Wall Street Rebounds From Fed Selloff

Stocks rebound on Thursday following a knee-jerk selloff late Wednesday tied to the Federal Reserve's rate hike outlook.

Stock Futures Trade Lower as Consumer Prices Hit Two-Year High

Stock Futures Trade Lower as Consumer Prices Hit Two-Year High

Stock futures are lower on Thursday as consumer prices hit their highest level in two years, underscoring the Federal Reserve's need to normalize monetary policy to deal with inflationary pressures.

Eli Lilly's 2017 Guidance Pleases Investors as Shares Soar

Eli Lilly's 2017 Guidance Pleases Investors as Shares Soar

Eli Lilly posts better-than-expected guidance for 2017, sending its share price soaring in premarket trading.